Drug intelligence / Profile preview

NEX-22

Development stage: Phase 1
Lead developer: Nanexa
Modality: Drug Delivery Systems
Administration: Subcutaneous

Overview

NEX-22 is a long-acting depot formulation of liraglutide, a GLP-1 analog, developed by Nanexa AB using their proprietary PharmaShell® drug delivery technology. This formulation is designed to be administered as a monthly subcutaneous injection, representing a significant improvement over the current daily injection requirement for liraglutide. The PharmaShell® technology utilizes Atomic Layer Deposition (ALD) to create a thin shell around pharmaceutical particles, enabling controlled release of the active ingredient over an extended period, approximately 28 days. Early clinical trials have shown a potentially reduced incidence of common GLP-1-associated gastrointestinal side effects compared to standard liraglutide treatment.

Other names: NEX-22NEX22NEX 22

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on NEX-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEX-22.

Explore the full profile